BiotechTube

CAB-AXL-ADC + PD-1 inhibitor

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Undifferentiated Pleomorphic Sarcoma

Conditions

Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma

Trial Timeline

Feb 15, 2018 → Jan 8, 2025

NCT ID
NCT03425279

About CAB-AXL-ADC + PD-1 inhibitor

CAB-AXL-ADC + PD-1 inhibitor is a phase 1/2 stage product being developed by BioAtla for Undifferentiated Pleomorphic Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03425279. Target conditions include Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (2)

NCT IDPhaseStatus
NCT04681131Phase 2Completed
NCT03425279Phase 1/2Completed

Competing Products

1 competing product in Undifferentiated Pleomorphic Sarcoma

See all competitors
ProductCompanyStageHype Score
Pembrolizumab + Cisplatin + Docetaxel + CarboplatinMerckPhase 2
52

Other Products from BioAtla

CAB-AXL-ADC + PD-1 inhibitorPhase 2
44
Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + CetuximabPhase 2
44
Durvalumab + BA3011 + BA3021 + ENB003 + ToripalimabPhase 2
44
BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta)Phase 1/2
33
CAB-ROR2-ADC + PD-1 inhibitorPhase 1/2
33